entecavir and baicalin

Although current antiviral treatments (nucleoside analogs, NAs) for chronic hepatitis B virus (HBV) infection are effective in suppressing HBV-DNA replication, their clinical outcomes can be compromised by the increasing drug resistance and the inefficiency in promoting HBsAg/HBeAg seroconversion.. In this study, we will explore possible effects and mechanism of a natural product baicalin (BA) with the anti-HBV efficacy of entecavir (ETV), a first-line anti-HBV drug, in HBV-DNA, HBsAg/HBeAg seroconversion and drug-resistance.. The co-effects of BA and ETV were conducted in wild-type/NA-resistance mutant HBV cell lines and DHBV-infected duckling models. HBV-DNA/RNAs, HBsAg/HBeAg, host factors (hepatocyte nuclear factors) were explored for possible anti-HBV mechanism.. BA could significantly enhance and reduced HBsAg and HBeAg in hepG2.2.15, a wild-type HBV cell line. Co-treatment of BA and ETV had a more dramatic effect in NA-resistant HBV

Topics: Animals; Animals, Newborn; Antiviral Agents; Biomarkers; Disease Models, Animal; DNA, Viral; Dose-Response Relationship, Drug; Drug Resistance, Viral; Drug Therapy, Combination; Ducks; Flavonoids; Guanine; Hep G2 Cells; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocyte Nuclear Factor 1-alpha; Hepatocyte Nuclear Factor 4; Host-Pathogen Interactions; Humans; RNA, Viral; Time Factors; Transcription, Genetic; Transfection; Viral Load